Displaying 1 - 12 of 18
Immune-Mediated and Cholestatic Diseases
3

CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
3

CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
3

CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
3

Novo Nordisk: Navigating MASH patient care - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
3

Novo Nordisk: Navigating MASH patient care - EASL Congress 2024

View